SHK-based pharmaceutical compositions and methods of manufacturing and using the same
Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.
1. A pharmaceutical composition comprising a pharmaceutically acceptable salt of an ShK polypeptide having the sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the ShK polypeptide is attached to an organic or inorganic chemical entity that has an anionic charge, and the C-terminus is an acid or an amide, wherein the pH of the pharmaceutical composition is between 5 and 7 and the pharmaceutical composition further comprises a surfactant in an amount effective to dissolve the ShK polypeptide in an aqueous carrier.
2. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition is contained in a sterile glass vial and is stored at −70° C.
3. The pharmaceutical composition of claim 1 formulated for subcutaneous administration.
4. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition is contained in a sterile syringe.
5. A unit of manufacture for pharmaceutical use comprising:
a pharmaceutical composition comprising a pharmaceutically acceptable salt of an ShK polypeptide having the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, wherein the ShK polypeptide is attached to an organic or inorganic chemical entity that has an anionic charge, and the C-terminus is an acid or an amide, and instructions for diluting and preparing the pharmaceutical composition for administration to a human, wherein the pH of the pharmaceutical composition is between 5 and 7 and the pharmaceutical composition further comprises a surfactant in an amount effective to dissolve the ShK polypeptide in an aqueous carrier, and wherein the pharmaceutical composition is contained in at least one glass vial prepared under sterile conditions such that the pharmaceutical composition within the at least one glass vial is stable for at least six months at −70° C.
6. A unit of manufacture for pharmaceutical use comprising:
a pharmaceutical composition comprising a pharmaceutically acceptable salt of an ShK polypeptide having the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, wherein the ShK polypeptide is attached to an organic or inorganic chemical entity that has an anionic charge, and the C-terminus is an acid or an amide, and instructions for administering the pharmaceutical composition to a human, wherein the pH of the pharmaceutical composition is between 5 and 7 and the pharmaceutical composition further comprises a surfactant in an amount effective to dissolve the ShK polypeptide in an aqueous carrier, and wherein the pharmaceutical composition is contained in at least one sterile syringe.